Dysregulation of the mTOR pathway in p53-deficient mice

Cancer Biology and Therapy

Volumn 14, Issue 12, 2013, Pages 1182-1188

  Leontieva, Olga V ^a   Novototskaya, Liliya R ^a   Paszkiewicz, Geraldine M ^a   Komarova, Elena A ^a   Gudkov, Andrei V ^a   Blagosklonny, Mikhail V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aging; Cancer; Inflammation; MTOR; P53; Rapalog; Rapamycin; Senescence

Indexed keywords

ENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHORYLATED S6; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN C; UNCLASSIFIED DRUG; MTOR PROTEIN, MOUSE; SOMATOMEDIN C RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HEART; HYPERINSULINEMIA; LIFE EXTENSION; LIVER; MALE; MOUSE; NONHUMAN; RADIATION INJURY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; ANTIBODY SPECIFICITY; CARDIAC MUSCLE; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; LIVER; MICE, KNOCKOUT; MYOCARDIUM; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891783663     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26947     Document Type: Article

References (88)

1. Vogelstein B, Lane DP, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675
2. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ 2007; 14:3-9; PMID:17068503; http://dx.doi.org/10.1038/sj.cdd.4402058 (Pubitemid 44911889)
3. Gudkov AV, Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 2007; 16(Spec No 1):R67-72; PMID:17613549; http://dx.doi.org/10.1093/hmg/ddm052 (Pubitemid 47241844)
4. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58; PMID:19776744; http://dx.doi.org/10.1038/nrc2723
5. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j. cell.2009.04.037
6. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269-83; PMID:22682249; http://dx.doi.org/10.1016/j. cell.2012.04.026
7. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) 2012; 4:450-5; PMID:22869016
8. Zhu Y, Prives C. p53 and Metabolism: The GAMT Connection. Mol Cell 2009; 36:351-2; PMID:19917243; http://dx.doi.org/10.1016/j. molcel.2009.10.026
9. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20:427-34; PMID:20399660; http://dx.doi.org/10.1016/j. tcb.2010.03.004
10. Altilia S, Santoro A, Malagoli D, Lanzarini C, Ballesteros Álvarez JA, Galazzo G, Porter DC, Crocco P, Rose G, Passarino G, et al. TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging (Albany NY) 2012; 4:28-39; PMID:22289634
11. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011; 2:948-57; PMID:22248668
12. Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013; 110:E89-98; PMID:23236145; http://dx.doi.org/10.1073/pnas.1216922110
13. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 2005; 102:17448-53; PMID:16287968; http://dx.doi.org/10.1073/pnas.0508888102 (Pubitemid 41740886)
14. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8:4168-75; PMID:20054236; http://dx.doi.org/10. 4161/cc.8.24.10800
15. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 2002; 21:5325-34; PMID:12149653; http://dx.doi.org/10.1038/ sj.onc.1205662 (Pubitemid 34948143)
16. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001; 8:317-25; PMID:11545734; http://dx.doi.org/10.1016/S1097-2765(01)00323-9 (Pubitemid 32831549)
17. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005; 102:8204-9; PMID:15928081; http://dx.doi.org/10.1073/pnas.0502857102 (Pubitemid 40800067)
18. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75; PMID:16452501; http://dx.doi.org/10.1101/gad.1363206 (Pubitemid 43200281)
19. Levine AJ, Harris CR, Puzio-Kuter AM. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway. Oncotarget 2012; 3:1301-7; PMID:23211569
20. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol 2013; 14:R32; PMID:23594524; http://dx.doi.org/10.1186/gb-2013-14-4-r32
21. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010; 107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.1002298107
22. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344-52; PMID:20606252
23. Tucci P. Caloric restriction: is mammalian life extension linked to p53? Aging (Albany NY) 2012; 4:525-34; PMID:22983298
24. de Keizer PL, Laberge RM, Campisi J. p53: Pro-aging or pro-longevity? Aging (Albany NY) 2010; 2:377-9; PMID:20657035
25. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6:2853-68; PMID:19053174; http://dx.doi.org/10.1371/ journal.pbio.0060301
26. Lee JH, Bodmer R, Bier E, Karin M. Sestrins at the crossroad between stress and aging. Aging (Albany NY) 2010; 2:369-74; PMID:20606249
27. Horikawa I, Fujita K, Harris CC. p53 governs telomere regulation feedback too, via TRF2. Aging (Albany NY) 2011; 3:26-32; PMID:21266744
28. Dulic V. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence? Aging (Albany NY) 2011; 3:3-4; PMID:21248373
29. Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535-7; PMID:20876940
30. McGee MD, Day N, Graham J, Melov S. cep-1/p53-dependent dysplastic pathology of the aging C. elegans gonad. Aging (Albany NY) 2012; 4:256-69; PMID:22562940
31. Chao SK, Horwitz SB, McDaid HM. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget 2011; 2:89-98; PMID:21399233
32. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924-35; PMID:21212465
33. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A 2012; 109:13314-8; PMID:22847439; http://dx.doi.org/10.1073/pnas.1205690109
34. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159-65; PMID:22394614
35. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012; 11:2391-401; PMID:22627671; http://dx.doi.org/10.4161/cc.20683
36. Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642-9; PMID:23187803; http://dx.doi.org/10.4161/cc.22937
37. Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 2002; 34:1401-14; PMID:12200035; http://dx.doi.org/10.1016/S1357-2725(02)00053-5 (Pubitemid 35251811)
38. Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromalepithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 2005; 118:485-96; PMID:15657080; http://dx.doi.org/10.1242/jcs.01635 (Pubitemid 40310116)
39. Martens JW, Sieuwerts AM, Bolt-deVries J, Bosma PT, Swiggers SJ, Klijn JG, Foekens JA. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 2003; 89:393-404; PMID:12574821 (Pubitemid 36227292)
40. Mikheev AM, Stoll EA, Ramakrishna R, Mikheeva SA, Horner PJ, Rostomily RC. Geropotency: increased malignant potential of aging neural progenitors. Aging (Albany NY) 2012; 4:854-5; PMID:23257545
41. Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012; 11:2285-302; PMID:22684298; http://dx.doi.org/10.4161/cc.20718
42. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278-93; PMID:22698676; http://dx.doi.org/10.1016/j.ajpath.2012.03.017
43. Prabhu VV, Warfel NA, El-Deiry WS. CTGFmediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle 2012; 11:2592-3; PMID:22751431; http://dx.doi.org/10.4161/cc.21240
44. Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY) 2011; 3:407-16; PMID:21515933
45. Greaves M. Leukemogenesis and ageing: 'fit for transformation'? Aging (Albany, NY Online) 2011; 3:79-80
46. Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection? Aging (Albany NY) 2011; 3:643-56; PMID:21765201
47. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Viña J, Blasco MA, Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007; 448:375-9; PMID:17637672; http://dx.doi.org/10.1038/nature05949 (Pubitemid 47080339)
48. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID:18769112; http://dx.doi.org/10.4161/cbt.7.10.6663
49. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130-41; PMID:22246147
50. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148-57; PMID:21386129
51. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther 2012; 13:1349-54; PMID:23151465; http://dx.doi.org/10.4161/ cbt.22859
52. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) 2012; 4:320-9; PMID:22589237
53. Stipp D. A new path to longevity. Sci Am 2012; 306:32-9; PMID:22279832; http://dx.doi.org/10.1038/scientificamerican0112-32
54. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11:453-65; PMID:20519118; http://dx.doi.org/10.1016/j. cmet.2010.05.001
55. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493:338-45; PMID:23325216; http://dx.doi.org/10.1038/nature11861
56. Kaeberlein M. Longevity and aging. F1000Prime Rep 2013; 5:5; PMID:23513177; http://dx.doi.org/10.12703/P5-5
57. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35-46; PMID:20074526; http://dx.doi.org/10. 1016/j. cmet.2009.11.010
58. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013; 12:851-62; PMID:23734717; http://dx.doi.org/10.1111/acel.12109
59. Blagosklonny MV. How to save Medicare: the antiaging remedy. Aging (Albany NY) 2012; 4:547-52; PMID:22915707
60. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/10.1038/356215a0
61. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr., Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14:16-22; PMID:7546219; http://dx.doi.org/10.1002/mc.2940140105
62. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7; PMID:7922305; http://dx.doi.org/10.1016/S0960-9822(00)00002-6
63. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/-mice. Aging (Albany NY) 2012; 4:709-14; PMID:23123616
64. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/-mice by delaying carcinogenesis. Aging (Albany NY) 2012; 4:715-22; PMID:23117593
65. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany NY) 2012; 4:660-1; PMID:23128359
66. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, et al. p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19:1030-2; PMID:15811878 (Pubitemid 40827741)
67. Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2011; 2:503-16; PMID:21779518; http://dx.doi.org/10.1177/ 1947601911409747
68. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 1999; 5:335-9; PMID:10086392; http://dx.doi.org/10.1038/6585 (Pubitemid 29124372)
69. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001; 88:780-6; PMID:11325869; http://dx.doi.org/10.1161/hh0801. 089261 (Pubitemid 32429973)
70. Mercer J, Bennett M. The role of p53 in atherosclerosis. Cell Cycle 2006; 5:1907-9; PMID:16929177; http://dx.doi.org/10.4161/cc.5.17.3166 (Pubitemid 44435291)
71. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) 2012; 4:899-916; PMID:23443503
72. Leontieva OV, Paszkiewicz G, Demidenko ZN, Blagosklonny MV. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis 2013; 4:e472; PMID:23348586; http://dx.doi.org/10. 1038/cddis.2012.202
73. van Heemst D, Beekman M, Mooijaart SP, Heijmans BT, Brandt BW, Zwaan BJ, Slagboom PE, Westendorp RG. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 2005; 4:79-85; PMID:15771611; http://dx.doi.org/10.1111/j. 1474-9728.2005.00148.x (Pubitemid 41632906)
74. Yuan R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, Bogue MA, Mills KD, Peters LL, Bult CJ, et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 2009; 8:277-87; PMID:19627267; http://dx.doi.org/10.1111/j.1474- 9726.2009.00478.x
75. Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, Lamberts SW, Monti D, Bucci L, Cevenini E, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) 2012; 4:580-9; PMID:22983440
76. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431:200-5; PMID:15306821; http://dx.doi.org/10.1038/nature02866 (Pubitemid 39243474)
77. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650-6; PMID:15380067; http://dx.doi.org/10.1016/j. cub.2004.08.026 (Pubitemid 39239362)
78. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140-4; PMID:19797661; http://dx.doi.org/10.1126/science.1177221
79. Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin sensitivity as a key mediator of growth hormone actions on longevity. J Gerontol A Biol Sci Med Sci 2009; 64:516-21; PMID:19304940; http://dx.doi.org/10.1093/ gerona/glp024
80. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 2008; 105:3438-42; PMID:18316725; http://dx.doi.org/10.1073/pnas.0705467105 (Pubitemid 351723571)
81. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003; 299:1346-51; PMID:12610294; http://dx.doi.org/10.1126/science.1081447 (Pubitemid 36254639)
82. Bartke A. Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol Metab 2006; 17:33-5; PMID:16458526; http://dx.doi.org/10.1016/j.tem.2006.01.002
83. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13; PMID:21325617; http://dx.doi.org/10.1126/scitranslmed.3001845
84. Bartke A. Healthy aging: is smaller better?-a mini-review. Gerontology 2012; 58:337-43; PMID:22261798; http://dx.doi.org/10.1159/000335166
85. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapyimplications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497
86. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3:1566-75; PMID:23248156
87. Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 1994; 91:7036-40; PMID:8041741; http://dx.doi.org/10.1073/pnas.91.15.7036 (Pubitemid 24226797)
88. Leonova KI, Shneyder J, Antoch MP, Toshkov IA, Novototskaya LR, Komarov PG, Komarova EA, Gudkov AV. A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 2010; 9:1434-43; PMID:20404530; http://dx.doi.org/10.4161/ cc.9.7.11508